Table 4. Dose intensities (first 12 weeks; percentage of patients with <80%) on line only.
|
Arms A+C (no cetuximab)
|
Arm B (cetuximab)
|
||||
|---|---|---|---|---|---|
| OxMdG | XELOX | OxMdG | XELOX | Total | |
| Total | 203 | 333 | 102 | 166 | 804 |
| Complete data on first round of treatment (0–12 weeks) | 158 | 247 | 76 | 119 | 600 |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
|---|---|---|---|---|---|
| 5FU infusion | 3 (2) | 5 (7) | 8 (3) | ||
| 5FU bolus | 24 (15) | 16 (21) | 40 (17) | ||
| Capecitabine | 11 (4) | 17 (14) | 28 (8) | ||
| Oxaliplatin | 5 (3) | 4 (2) | 6 (8) | 14 (12) | 29 (5) |
| Cetuximab, day 1 | 1 (1) | 12 (10) | 13 (7) | ||
| Cetuximab, day 8 | 7 (9) | 23 (19) | 30 (15) | ||
| Cetuximab, day 15 | 29 (24) | 29 (24) |
5FU=5-fluorouracil.